Benchpress,

Just my 2 cents...I have been around for sometime and know various ways stocks get manipulated especially those that are waiting for binary events such as PDUFA dates. IMHO, this is one great buying opportunity before the approval.

The stagnation looks like started to frustrate few retail investors like yourself and they start to unload...this is exactly what seasoned investors expect and they scoop up shares cheaply taking advantage of these 'dips'. Nothing has changed since it hit a high of 3:70 other than slow crawl of time.

If you are out, you are out..wish you a good return on your remaining 50% unless you choose to 'dump' them as well.

MNTA - it's just sad that insiders have screwed up their own success by ill-timing the tax related sales. Looks like the pps could go lower than pre-approval level. No institution interest to scoop up big at these levels ??

If TEVA gets approal, this is a great blow to MNTA's 'proprietry' platform...IMHO

Doctors may still use Avastin off-label to treat breast cancer, but not the other cancers. This may then cause serious problems for patients whose insurance will not cover off-label drug usage and hence they may have to pay more ? Thx

FWIW, Craig WHeeler is on the board of RPTP (Raptor Pharma). RPTP P3 results are due by Q4 this year and has a promising drug platform too.

While reviewing the insider holders list, see Craig Wheeler's name who is CEO of MNTA, a very promising Biotech awaiting approval for their generic Lovenox.

interesting...

Good news indeed...this will be a billion dollar drug eventually.

Dew, what do you think of BIOD (Biodel) ? Other than goof up on their P3 trials in India, is there a fair chance FDA would approve their application come October ? TIA

Hang on..it will be at $3 soon..

Agree 100%....I never said getting the 'info' was anything but illegal. Downright these crooks need to be put in jail.

I just tried to explain the 'mechanics' on how they (crooks) scoop up the cheap shares.

I think this is what happened which doesn't seem too far fetched.

Someone who knew the positive news (hedge fund probably) shorted or sold substantial (100K would do) at market while having buy orders in place much lower to scoop up all the stop losses.

THis is not illegal and simply some smart fund manager took advantage of all cumulative stop losses the retailers had on this stock.

FYI, I have done it myself albeit on much smaller scale (sold 5k at market only to have my limit buy orders at lower price get filled.

Obviously there is risk if the Sale at Mark may get aborbed quickly that the seller would end up loosing his shares. But keep in mind, in POZN situation, everyone including my neighbour & my lawnmower man was maxed out. The only mistake such retailers did was to have that STOP Losses order.

Bottom line, smart money stole the cheap shares like a candy from a kid. Did anyone hear of 'shaking a tree' ??

I think there was a negative leak. FDS normally announce approvals during the market hrs (with a halt) and non-approvals after or before market is open.

With no halt yet, I wonder which way it's going to today...

Could it be Mutual Pharms's generic Aricept ?

actually it's two different transactions of equal value totaling 56 million. My response was wrong too as 49 brazillian reals equals 19 million in US $.

Annual sales is not correct it should read 19 million ?

http://www.marketwatch.com/story/four-biotechs-to-watch-in-april-2010-04-01?siteid=yhoof

Antares Pharma Inc. /quotes/comstock/14*!ais/quotes/nls/ais (AIS 1.67, +0.07, +4.38%) makes drug-delivery systems that are regulated as devices -- pen injectors, needle-free injectors, disintegrating tablets and transdermal gels. The reason I am so bullish on this stock is because of its four-device deal with generic giant Teva Pharmaceutical /quotes/comstock/15*!teva/quotes/nls/teva (TEVA 63.92, +0.16, +0.25%) . This gives small-cap AIS a blue-chip reach.

Here's how it works: Antares provides Teva with a medical product, such as its needle-free injector, and Teva buys the device from Antares and loads it with a medication like its human growth hormone TevTropin. As Teva aggressively markets its products and gains market share, Antares shares in the rewards

Teva expects to take 10% of the U.S. human growth hormone market, which is mostly abnormally short children who would rather not get stuck with a needle. Antares is sure to ride Teva's coattails to big profits on this medication. And looking forward, I expect at least one more product announcement from Teva in 2010.

On top of that, another partner, BioSante Pharmaceuticals Inc. /quotes/comstock/15*!bpax/quotes/nls/bpax (BPAX 1.86, +0.04, +2.20%) , has sublicensed an estradiol gel for hot flashes that is on the market now, and has the "female Viagra" testosterone gel in Phase III trials ending in 2010. Antares' business model is to develop the products, partner them out and collect royalties.

The stock has been around $1.50 recently, and I think it could more than triple to $5 over the next 12 months. Buy it AIS in April before it takes off.

ALl, I am closer to a hedge fund called Ayer Capital Management that has boat load of shares on RPTP. I hear this company has solid track record. Expecting at least $3 upon impending news.

POZN might cross 10 today..BIDS are piling up

Just thought we will be 15+ with approval and all this AM !!

is POZEN halted ? No volume this AM ?

Glad I did not buy into your argument on APPA You were so bullish on the stock's prospects of winning the approval...to be fair you did warn that it's dicey to be long after PDUFA date with FDA being so unpredictable et all..

Agreed...DD missed the boat...I did not buy any after seeing DD's comments and I am kicking myself now..

Quick question, Dew..under 10b5-1, is there a restriction on how much shares they can sell though the transaction itself is automatic ? I wonder on approval, the insiders may decide to unload sizable amount. The amounts based on all past sales vary in wide degree. TIA

What from what I heard the whole clan who founded Ranbaxy jumped ship after selling their stake and the quality problems existed even before then. NOt sure how Japenese could have overlooked this fact when they bought Ranbaxy

I agree 100%..smells like Nuvello on many counts..

While I have a position, I am concerned too many folks are loaded up to gill waiting for double or triple homeruns. Hope we keep the momentum going considering risk is expontential to new buyers who are gettting in now.

India always been a double edged sword for big US pharmas. On one hand they want their patents to be protected but they continue to look into taping cheap resources even for highly skilled R&D not to speak of running clinical trials.

With no serious legal controls, US pharmas' outsourced R&D is one easy source for Indian generics companies to 'peek' thanks to resource attritions.

Thanks..in that case

I would have worded (bold/italics are mine)

WHile I don't remember all the details, the potential success of P3 Sonoma trial was over-hyped on several CC briefings.

What I never could understand (and neither most of the investor community) as how alfimeprase could restore flow to 50% of occluded catheters in 15 minutes or less after the first dose (demonstrated in their P2 trial) but failed in two pivotal P3 studies - one in actue peripheral arterial occlusion and the other in catheter occlusion.

THe management never clarified as to what went wrong ; no wonder several law suites were filed prior to their reverse merger with ARCA Pharma.

There was a blurb that FDA's P3 protocol requirement was very stringent but Nuvello did not articulate that aspect clearly in their disclosures to investors.

Ted Love is one hell of a crook who took everyone for ride when he was at Nuvello. These guys seem to have stronger half-life than a cockroach under a sofa.

I am bit disappointed on not seeing any follow-thru after the last weekend SCIA conference.

We might settle down at high 20's (cents) for a while before another news pushes up.

SCIA Presentation today..

Health Discovery Corporation -- (OTC.BB:HDVY - News) -- www.healthdiscoverycorp.com -- As previously announced, HDVY recently entered into royalty-bearing licenses for its new urine-based prostate cancer test with Quest Diagnostics Inc. and Abbott Laboratories for development and commercialization. The Company also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories and Clarient Inc. for development and commercialization. "The Company's minority-owned subsidiary, Smart Personalized Medicine LLC, recently entered into a licensing agreement with a world-renowned international cancer center to develop a breast cancer prognostic test. Along with the Company, the subsidiary is currently in discussions with a national clinical laboratory for development and commercialization of the test

Agree one hundered percent !

$3.5 to $4 upon approval.

What pullback ? Don't expect any until we hit 0.50 With today's news, the stock will get attention all over this weekend and Monday should be another leg up.

I think folks who missed to load up < 0.30 may never get that chance.

Agree with your assumptions..looks like we should be hitting $2 by end of next week based on buy interest today..